Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) is encoded by the gene EPM2A. EPM2A is a member of the protein-tyrosine phosphatase family. EPM2A is a dual-specificity phosphatase that acts on complex carbohydrates to prevent glycogen hyperphosphorylation and the formation of insoluble aggregates. EPM2A promotes the ubiquitination of proteins involved in glycogen metabolism via its interactions with the E3 ubiquitin ligase NHLRC1/malin. EPM2A is expressed in the heart, skeletal muscle, kidney, pancreas, and the brain. Diseases associated with EPM2A include Myoclonic Epilepsy of Lafora, Myoclonic Epilepsy of Unverricht And Lundborg, and benign epilepsy with centrotemporal spikes.
Purified by Protein A chromatography
Fusion protein amino acids 1-331 (full-length) of human Laforin (accession number O095278) produced recombinantly in E. Coli
Aliquot and store at ≤ -20°C for long term storage. For short term storage, store at 2-8°C. For maximum recovery of product, centrifuge the vial prior to removing the cap.
Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography and conjugation of purified mAb. Purified mAbs are >90% specific antibody.
PBS with 0.09% azide
FL594 Ex: 594 nm, Em: 615 nm
No cross-reactivity reported
Each new lot of antibody is quality control tested on cells overexpressing target protein and confirmed to give the expected staining pattern.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.